Scarica l'app Stockscreener
10.45
4.42%
0.54
Precedente Chiudi:
$9.91
Aprire:
$10.04
Volume 24 ore:
550.57K
Relative Volume:
0.57
Capitalizzazione di mercato:
$1.11B
Reddito:
$247.00M
Utile/perdita netta:
$-249.00M
Rapporto P/E:
-3.3819
EPS:
-3.09
Flusso di cassa netto:
$-267.00M
1 W Prestazione:
+14.22%
1M Prestazione:
+14.60%
6M Prestazione:
-21.01%
1 anno Prestazione:
-34.21%
Intervallo 1D:
$9.97
$10.51
Intervallo di 1 settimana:
$8.88
$10.51
Portata 52W:
$6.50
$18.98
Arcus Biosciences Inc Stock (RCUS) Company Profile
Nome
Arcus Biosciences Inc
Settore
Industria
Telefono
(510) 694-6200
Indirizzo
3928 POINT EDEN WAY, HAYWARD, CA
Confronta RCUS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
10.42 | 1.07B | 247.00M | -249.00M | -267.00M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.03 | 101.51B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
578.13 | 59.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
447.68 | 56.69B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
652.31 | 39.57B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
319.67 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-26 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2024-10-21 | Iniziato | H.C. Wainwright | Neutral |
| 2024-10-08 | Iniziato | Wells Fargo | Overweight |
| 2022-11-18 | Iniziato | BofA Securities | Neutral |
| 2022-10-11 | Iniziato | Morgan Stanley | Overweight |
| 2021-10-15 | Ripresa | BTIG Research | Buy |
| 2020-11-24 | Iniziato | Berenberg | Buy |
| 2020-11-23 | Iniziato | Evercore ISI | Outperform |
| 2020-04-03 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-09-27 | Iniziato | Mizuho | Buy |
| 2019-05-24 | Ripresa | Citigroup | Buy |
| 2018-10-09 | Iniziato | Wedbush | Outperform |
| 2018-04-09 | Iniziato | Citigroup | Buy |
| 2018-04-09 | Iniziato | Goldman | Neutral |
| 2018-04-09 | Iniziato | Leerink Partners | Outperform |
Mostra tutto
Arcus Biosciences Inc Borsa (RCUS) Ultime notizie
Will Arcus Biosciences Inc. Sustain Its Chart Breakout2025 Top Gainers & Fast Entry Momentum Trade Alerts - beatles.ru
Arcus Biosciences, Inc. (RCUS) Reports Break-Even Earnings for Q2 - MSN
Arcus Biosciences’ SWOT analysis: stock’s potential hinges on HIF-2alpha data - Investing.com
Jim Cramer Recommends Uranium Energy Corp., Warns Against Overreliance on Arcus Biosciences. - AInvest
Jim Cramer Recommends This Energy Stock, But Don't 'Bank It All' On Arcus - Benzinga
What machine learning models say about Arcus Biosciences Inc.Weekly Profit Report & Expert Approved Trade Ideas - Newser
Why Arcus Biosciences Inc. stock attracts strong analyst attentionWeekly Trade Analysis & Fast Moving Stock Trade Plans - Newser
New Product Launches: Will They Boost Arcus Biosciences Inc. Stock in 2025July 2025 Big Picture & Real-Time Chart Breakout Alerts - Newser
What institutional flow reveals about Arcus Biosciences Inc.Earnings Growth Report & Risk Managed Investment Entry Signals - Newser
Will Arcus Biosciences Inc. Hold Gains Into CloseReliable Alerts for Daily Stock Movers Released - beatles.ru
Arcus Biosciences (NYSE:RCUS) Upgraded at Wall Street Zen - Defense World
How to escape a deep drawdown in Arcus Biosciences Inc.Free Smart Trade Plans With Risk Protection - Newser
Arcus Biosciences, Inc. (NYSE:RCUS) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Cantor Fitzgerald Issues Positive Forecast for RCUS Earnings - Defense World
Wedbush Forecasts Lower Earnings for Arcus Biosciences - Defense World
Q3 EPS Forecast for Arcus Biosciences Reduced by Analyst - Defense World
Custom watchlist performance reports with Arcus Biosciences Inc.AI Volatility Forecast and Risk Monitor - Newser
Arcus Biosciences Q2 Earnings and Catalysts Ahead: A Risky Buy for 12 Months - AInvest
Arcus BiosciencesA Risky Buy Ahead Of Pivotal, Catalyst Rich 12 Months (NYSE:RCUS) - Seeking Alpha
Trapped Investors in Arcus Biosciences Inc. Await Breakout SignalNews Based Entry Opportunity Alerts Detected - beatles.ru
Arcus Biosciences, Inc. (NYSE:RCUS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - Yahoo Finance
Zurcher Kantonalbank Zurich Cantonalbank Buys 2,524 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Arcus Biosciences Inc. Stock Recovery Path — Analyst BreakdownReal Time Stock Movement Analysis Indicates Breakout - beatles.ru
Gilead and Arcus Advance Promising Colorectal Cancer Study - TipRanks
Arcus Biosciences Tops Revenue Forecasts And Drives Pipeline Growth - Finimize
Gilead and Arcus Biosciences’ Promising Study on Advanced Gastrointestinal Cancers - TipRanks
A Quick Look at Today's Ratings for Arcus Biosciences(RCUS.US), With a Forecast Between $14 to $52 - 富途牛牛
Wells Fargo Adjusts Price Target for Arcus Biosciences (RCUS) | - GuruFocus
H.C. Wainwright Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Maintains Target Price $24 - 富途牛牛
Morgan Stanley Lifts Price Target on Arcus Biosciences to $23 From $22, Keeps Overweight Rating - MarketScreener
Decoding Arcus Biosciences Inc (RCUS): A Strategic SWOT Insight - GuruFocus
Arcus Biosciences Reports Strong Q2 2025 Results - TipRanks
Arcus Biosciences earnings beat by $0.01, revenue topped estimates - Investing.com Canada
Arcus Biosciences Q2 revenue beats analyst expectations - MarketScreener
Arcus Biosciences Reports Second-Quarter 2025 Financial Results and Provides a Pipeline Update - Stock Titan
Universal Beteiligungs und Servicegesellschaft mbH Takes Position in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Is Arcus Biosciences (NYSE:RCUS) Using Debt In A Risky Way? - 富途牛牛
When is Arcus Biosciences Inc. stock expected to show significant growthIdentify undervalued stocks ready to soar - Jammu Links News
How volatile is Arcus Biosciences Inc. stock compared to the marketTremendous gains - Jammu Links News
What are the technical indicators suggesting about Arcus Biosciences Inc.Free Wealth Planning Blueprint - Jammu Links News
What institutional investors are buying Arcus Biosciences Inc. stockHigh-yield investments - Jammu Links News
Should I hold or sell Arcus Biosciences Inc. stock in 2025Unlock powerful portfolio management tools - Jammu Links News
How does Arcus Biosciences Inc. compare to its industry peersOutstanding capital appreciation - Jammu Links News
What are the latest earnings results for Arcus Biosciences Inc.Outstanding risk-reward balance - Jammu Links News
Why is Arcus Biosciences Inc. stock attracting strong analyst attentionRealize consistent double-digit growth - Jammu Links News
Does Arcus Biosciences Inc. stock perform well during market downturnsTremendous gains - Jammu Links News
What catalysts could drive Arcus Biosciences Inc. stock higher in 2025Free Stock Movement Tracking - Jammu Links News
Arcus Biosciences’ Pancreatic Cancer Drug Quemliclustat Receives Orphan Drug Designation from FDA - MSN
How does Arcus Biosciences Inc. generate profit in a changing economyPost Market Planner That Work - Jammu Links News
Arcus Biosciences Advances Phase 1 Study of AB521 in Cancer Treatment - TipRanks
Will Arcus Biosciences Inc. bounce back from current supportEarly Breakout Entry Point Notifications Sent - metal.it
Arcus Biosciences Inc Azioni (RCUS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.06%
0.58%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):